Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Keros Therapeutics (KROS) Shares Outstanding (Diluted Average): 2020-2025

Historic Shares Outstanding (Diluted Average) for Keros Therapeutics (KROS) over the last 6 years, with Sep 2025 value amounting to $41.2 million.

  • Keros Therapeutics' Shares Outstanding (Diluted Average) rose 9.61% to $41.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $41.2 million, marking a year-over-year increase of 9.61%. This contributed to the annual value of $37.4 million for FY2024, which is 27.14% up from last year.
  • Latest data reveals that Keros Therapeutics reported Shares Outstanding (Diluted Average) of $41.2 million as of Q3 2025, which was up 0.12% from $41.2 million recorded in Q2 2025.
  • Over the past 5 years, Keros Therapeutics' Shares Outstanding (Diluted Average) peaked at $41.2 million during Q3 2025, and registered a low of $23.2 million during Q1 2021.
  • Its 3-year average for Shares Outstanding (Diluted Average) is $35.2 million, with a median of $36.1 million in 2024.
  • Data for Keros Therapeutics' Shares Outstanding (Diluted Average) shows a peak YoY soared of 50.48% (in 2021) over the last 5 years.
  • Over the past 5 years, Keros Therapeutics' Shares Outstanding (Diluted Average) (Quarterly) stood at $23.3 million in 2021, then climbed by 8.17% to $25.2 million in 2022, then rose by 16.66% to $29.4 million in 2023, then rose by 27.14% to $37.4 million in 2024, then increased by 9.61% to $41.2 million in 2025.
  • Its Shares Outstanding (Diluted Average) was $41.2 million in Q3 2025, compared to $41.2 million in Q2 2025 and $41.0 million in Q1 2025.